Advanced glycation end products and hyperglycaemia;Avanserte glykerte endeprodukter og hyperglykemi

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 2, 2006, Pages 155-158

  Omsland, Tone Kristin ^a   Bangstad, Hans Jacob ^b   Berg, Tore Julsrud ^c   Kolset, Svein Olav ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LIPID; PROTEIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

CELLULAR DISTRIBUTION; COMPLEX FORMATION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; EXTRACELLULAR SPACE; GENE CONTROL; GLYCATION; HUMAN; HYPERGLYCEMIA; PROTEIN MODIFICATION; RECEPTOR BINDING; REVIEW; SERUM; TISSUE LEVEL; URINARY EXCRETION; ATHEROSCLEROSIS; BIOSYNTHESIS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; METABOLISM;

ATHEROSCLEROSIS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; RECEPTORS, IMMUNOLOGIC;

EID: 33644819321     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
2. Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-80.
3. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
4. Kalousova M, Zima T, Tesar V et al. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004; 27: 18-28.
5. Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41: S42-7.
6. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 2005; 38: 103-15.
7. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
8. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49: 9-13.
9. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
10. Dyer DG, Dunn JA, Thorpe SR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-9.
11. Reddy S, Bichler J, Wells-Knecht KJ et al. N epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-8.
12. McCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-8.
13. Miura J, Yamagishi S, Uchigata Y et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003; 17: 16-21.
14. Makita Z, Vlassara H, Cerami A et al. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-8.
15. Singh R, Barden A, Mori T et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46.
16. Skolnik EY, Yang Z, Makita Z et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-9.
17. Svistounov DN, Berg TJ, McCourt PA et al. Lack of recognition of Nepsilon-(carboxymethyl)lysine by the mouse liver reticulo-endothelial system: implications for pathophysiology. Biochem Biophys Res Commun 2003; 309: 786-91.
18. Yan SF, Ramasamy R, Naka Y et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-69.
19. Raj DS, Choudhury D, Welbourne TC et al. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-80.
20. Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-7.
21. Sady C, Jiang CL, Chellan P et al. Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins. Biochim Biophys Acta 2000; 1481: 255-64.
22. Li JH, Wang W, Huang XR et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 1389-97.
23. Tanaka N, Yonekura H, Yamagishi S et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781-90.
24. Bucciarelli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-28.
25. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-74.
26. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-73.
27. Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J Pathol 2003; 200: 537-46.
28. Osterby R, Parving HH, Hommel E et al. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes 1990; 39: 1057-63.
29. Makino H, Yamasaki Y, Haramoto T et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 1993; 68: 45-55.
30. Berg TJ, Bangstad HJ, Torjesen PA et al. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-5.
31. Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
32. Yang CW, Vlassara H, Peten EP et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436-40.
33. Borrebaek J, Prydz K, Fjeldstad K et al. The AGE product N epsilon-(carboxymethyl)lysine serum albumin is a modulator of proteoglycan expression in polarized cultured kidney epithelial cells. Diabetologia 2001; 44: 488-94.
34. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
35. Vlassara H, Fuh H, Makita Z et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-7.
36. Kilhovd BK, Juutilainen A, Lehto S et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25: 815-20.
37. Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 2004; 4: 441-6.
38. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010.
39. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53: 131-42.
40. Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-23.
41. Babaei-Jadidi R, Karachalias N, Ahmed N et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.